Literature DB >> 17434644

Gene manipulation through the use of small interfering RNA (siRNA): from in vitro to in vivo applications.

Lekha Dinesh Kumar1, Alan R Clarke.   

Abstract

The conventional approach to investigate genotype-phenotype relationships has been the generation of gene targeted murine strains. However, the emergence of RNAi technologies has opened the possibility of much more rapid (and indeed more cost effective) genetic manipulation in vivo at the level of the transcriptome. Successful application of RNAi in vivo depends on intracellular targeted delivery of siRNA/shRNA molecules for efficient knockdown of the desired gene. In this review, we discuss the rationale and different strategies of using siRNA/shRNA for accomplishing the silencing of targeted genes in a spatial and /or temporally regulated manner. We also summarise the steps involved in extending these approaches to in vivo applications, with a specific focus upon the development of silencing in the mouse.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17434644     DOI: 10.1016/j.addr.2007.03.009

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  17 in total

1.  siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

Review 2.  Antisense makes sense in engineered regenerative medicine.

Authors:  Yongchang Yao; Chunming Wang; Rohan R Varshney; Dong-An Wang
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

3.  Strategy for a generic resistance to geminiviruses infecting tomato and papaya through in silico siRNA search.

Authors:  Sangeeta Saxena; Nidhi Singh; S A Ranade; Sunil G Babu
Journal:  Virus Genes       Date:  2011-08-06       Impact factor: 2.332

Review 4.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

5.  Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures.

Authors:  Ho Lun Wong; Zancong Shen; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  Mol Pharm       Date:  2011-03-29       Impact factor: 4.939

6.  Advances in Systemic siRNA Delivery.

Authors:  Qixin Leng; Martin C Woodle; Patrick Y Lu; A James Mixson
Journal:  Drugs Future       Date:  2009-09       Impact factor: 0.148

Review 7.  Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine.

Authors:  Hui Yi Xue; Shimeng Liu; Ho Lun Wong
Journal:  Nanomedicine (Lond)       Date:  2014-02       Impact factor: 5.307

Review 8.  Lipid-based systemic delivery of siRNA.

Authors:  Yu-Cheng Tseng; Subho Mozumdar; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2009-03-26       Impact factor: 15.470

9.  Acetylation of PAMAM dendrimers for cellular delivery of siRNA.

Authors:  Carolyn L Waite; Sarah M Sparks; Kathryn E Uhrich; Charles M Roth
Journal:  BMC Biotechnol       Date:  2009-04-23       Impact factor: 2.563

Review 10.  Epithelial cell apoptosis and neutrophil recruitment in acute lung injury-a unifying hypothesis? What we have learned from small interfering RNAs.

Authors:  Mario Perl; Joanne Lomas-Neira; Chun-Shiang Chung; Alfred Ayala
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.